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SUMMARY – Rosacea is a common chronic inflammatory cutaneous disease of unknown eti-
ology, characterized by remissions and exacerbations, presenting with centrofacial erythema and 
telangiectasias. It affects mainly adults around the age of 30 years and classically predominates in 
females. The pathophysiology of rosacea has not yet been fully understood. Risk factors are positive 
family history, very light skin phototype, sun exposure and consumption of spicy food or alcohol. 
Recently, there has been some evidence that some drugs or vitamins could be potential factors that 
can aggravate rosacea or induce rosacea-like symptoms. In this context, we present a 53-year-old 
female developing rosacea-like dermatitis due to a fixed combination of isoniazid and pyridoxine, 
which she was receiving along with rifampicin for the treatment of pulmonary tuberculosis. 
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Introduction
Rosacea is a common chronic inflammatory skin 
disease affecting blood vessels and pilosebaceous units. 
It mainly affects the central area of the face, present-
ing with many different clinical features. Rosacea 
occurs in adults, usually between 30 and 50 years of 
age, appearing more often in women. It is one of the 
most common diagnoses in the clinical dermatologic 
practice. The pathophysiology of rosacea has not yet 
been fully understood. Family history of the disease 
and very light skin phototype are among the most im-
portant risk factors. Moreover, some drugs are found 
to aggravate rosacea or induce rosacea-like symptoms. 
Herein, we report a 53-year-old female developing 
rosacea-like skin lesions due to a fixed combination 
of isoniazid and pyridoxine, which she was receiving 
along with rifampicin for pulmonary tuberculosis.
Case Report
A 53-year-old female was referred to our De-
partment for dermatologic evaluation of centrofacial 
erythema with disseminated erythematous papular 
lesions. Clinical symptoms were of three-day dura-
tion with a tendency of progression, accompanied by 
intensive itching and pain. Seven months prior to the 
examination, pulmonary tuberculosis had been di-
agnosed and the patient had received four drugs as a 
first-line antituberculotic regimen, including a fixed 
combination of isoniazid (INH) and pyridoxine, ri-
fampicin, ethambutol and pyrazinamide for three 
months, followed by dual therapy consisting of isoni-
azid (INH) and B6 in fixed combination and rifam-
picin given simultaneously. Prior to the initiation of 
isoniazid, N-acetyltransferase type 2 genotyping was 
performed to personalize the dose, which showed 
slow acetylator phenotype. Consequently, lower doses 
of medication were prescribed, including 300 mg of 
isoniazid and 18.75 mg of pyridoxine every other day. 
Clinical examination revealed diffuse centrofacial 
erythema with evident erythematous papules without 
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telangiectasias (Fig. 1). Subjective symptoms of skin 
itching and sensitivity were also present. The patient’s 
general condition was unremarkable, although she suf-
fered from occasionally intermittent fever and mild 
chest pain. Recent sun exposure and application of topi-
cal corticosteroids were excluded. Family and personal 
history in a sense of facial flushing and sensitivity was 
negative. Considering clinical presentation that was 
highly suggestive of rosacea and reports describing asso-
ciation of pyridoxine intake and rosacea-like dermatitis, 
we decided not to perform skin biopsy. Furthermore, 
since pyridoxine is part of antituberculotic therapy, we 
were not able to discontinue the use of the incriminated 
agent. Topical metronidazole and cold compresses were 
administered twice daily and the patient was advised to 
follow mandatory photoprotection. On post-therapeu-
tic follow up examination two weeks later, the lesions 
started to diminish, as well as the patient’s symptoms of 
sensitivity and pain (Fig. 2). Rapid complete regression 
was seen after discontinuation of isoniazid (INH) and 
pyridoxine therapy three months later. 
Discussion
Rosacea is a common chronic inflammatory cuta-
neous disease of unknown etiology. Identified triggers 
are genetic predisposition, very light skin phototype 
and external factors such as sun and high temperature 
exposure and diet1. Additionally, drugs and vitamins 
could also be possible triggers for rosacea-like der-
matitis2-6, including topical corticosteroids3 and im-
munomodulators2, epidermal growth factor receptor 
(EGFR) inhibitors6, phosphodiesterase-5 inhibitors5 
and vitamin B4,7-9. Although the exact mechanism of 
drug induced rosacea still remains unknown, nitric 
oxide and prostaglandins are factors that could cause 
vascular alterations inducing rosacea5,7,8. Furthermore, 
due to prolonged therapy with the incriminated drug, 
another potential factor could be irritation of the fol-
licular epithelium leading subsequently to an inflam-
matory reaction4,7. Some researchers suggest that drug 
induced rosacea-like dermatitis occurs in genetically 
predisposed individuals5,7, and vitamin B induced ro-
sacea appears to be more common in women7. Con-
cerning vitamin B inducing rosacea, few cases have 
been reported so far7-9. Vitamin B3 (niacin) has been 
associated with skin flushing4,7-12, whereas vitamins B2 
(riboflavin), B6 (pyridoxine) and B12 (cyanocobala-
min) have shown to be associated with exacerbation of 
acne vulgaris and outbreak of acneiform lesions4,7,10-12. 
Fig. 1. Diffuse centrofacial erythema 
with evident erythematous papules.
Fig. 2. Regression of skin lesions 
after conducting topical therapy with met-
ronidazole and cold compresses twice daily.
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Rosacea fulminans has been reported following the 
administration of vitamin B derivatives, but in most 
cases the reactions were associated with excess rec-
ommended daily doses4,7. Regarding therapy options, 
vitamin B-triggered rosacea, as well as other drug 
induced rosacea do not usually respond to standard 
rosacea treatments, but clinical symptoms tend to im-
prove rapidly upon withdrawal of the incriminating 
agent7,10. Our patient developed rosacea-like derma-
titis after prolonged therapy with a fixed-dose com-
bination of isoniazid (INH) 400 mg and pyridoxine 
(vitamin B6) 25 mg for current pulmonary tuberculo-
sis. Pyridoxine, vitamin B6, is a hydrosoluble vitamin, 
which is important for proper functioning of the ner-
vous system13. Isoniazid (INH) is a potent antimyco-
bacterial agent, which is thought to act by inhibition 
of mycolic acids of Mycobacterium tuberculosis, thus in-
hibiting its cell wall synthesis14. It is an effective and 
widely used first-line antituberculotic drug, but its use 
is related to the development of polyneuropathy, the 
well known toxicity associated with antituberculosis 
chemotherapy15,16, appearing as tingling sensation 
and paresthesias15-17. Although the exact mechanism 
whereby pyridoxine deficiency causes polyneuropathy 
is still unclear, some researchers suggest that isoniazid 
forms a complex with pyridoxine, resulting in defi-
ciency of biologically active pyridoxine15,16. The risk 
of isoniazid induced polyneuropathy depends on the 
dose of isoniazid used, acetylator genotype, and asso-
ciated risk factors such as older age, chronic alcohol-
ism, diabetes, malnutrition, HIV-infection, pregnan-
cy, lactation and usage of neurotoxic medication15,17. 
Isoniazid induced polyneuropathy is preventable and 
easily treatable with pyridoxine, which acts preven-
tively in low dosages and curatively in high dosages15. 
Therefore, pyridoxine is generally routinely prescribed 
and administered orally with isoniazid for tubercu-
losis patients in the industrialized world15-17. There is 
still tremendous variability in the recommendations 
regarding pyridoxine prophylaxis and therapy in the 
context of isoniazid treatment15. In our case, as the 
patient is a slow acetylator phenotype, she was on a 
lower dose of isoniazid and therefore also on a lower 
dose of pyridoxine, including 300 mg of isoniazid and 
18.75 mg of pyridoxine every other day. Therefore, the 
daily recommended dosage was not exceeded but still 
induced rosacea-like dermatitis. We report this case 
to draw attention to the rather rare skin side effect 
of vitamin B6 when used in dosages below the rec-
ommended daily dose, considering that this clinical 
presentation is usually associated with a dosage much 
higher than the suggested daily intake levels. This 
pyridoxine side effect, although relatively rare, is im-
portant to acknowledge, particularly in the areas with 
a high prevalence and incidence of tuberculosis, which 
may consequently result in a higher occurrence rate of 
this cutaneous adverse reaction. 
Conclusion
The etiopathology of rosacea remains still un-
known. Besides known triggering factors, one should 
be aware of drugs and vitamins as possible provok-
ing factors for development of rosacea or worsening 
pre-existing condition. Therefore, we emphasize the 
importance of pyridoxine (vitamin B6) as a potential 
trigger factor for rosacea. Although this side effect of 
pyridoxine is relatively uncommon it is important to 
identify it as it can have large impact on patient qual-
ity of life as well as treatment compliance during anti-
tuberculosis isoniazid therapy.
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Sažetak 
ROSACEIFORMNI DERMATITIS UZROKOVAN PIRIDOKSINOM
S. Rezaković, Z. Bukvić Mokos i Z. Paštar
Rosacea je kronična upalna bolest kože nepoznate etiologije, obilježena remisijama i egzacerbacijama te kliničkom 
slikom centrofacijalnog eritema i pojavom teleangiektazija. Javlja se u odrasloj dobi, pretežito u 30-tim godinama, nešto 
češće u žena. Patofiziologija rosaceje još uvijek nije do kraja razjašnjena. Čimbenici rizika za pojavu bolesti su pozitivna 
obiteljska anamneza, svijetli fototip kože, izlaganje sunčevoj svjetlosti te konzumacija alkohola, kofeina, toplih napitaka i 
začinjene hrane. Međutim, neka istraživanja ukazuju na to da određeni lijekovi i vitamini također mogu biti provocirajući 
čimbenici u nastanku rozaceje ili pogoršanju već postojeće bolesti. Predstavljamo 53-godišnju bolesnicu u koje se razvio 
rosaceiformni dermatitis nakon započinjanja terapije fiksnom kombinacijom izoniazida i piridoksina (Eutizon®B6) i rifam-
picina (Rimactan®) u sklopu liječenja tuberkuloze.
Ključne riječi: Piridoksin; Vitamin B6; Rozaceja – izazvana kemijskim supstancama
